Kinarus Therapeutics Holding AG
ISIN: CH0009115129 | Ticker: KNRS | LEI: 506700VDL70GGMHR5758
Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.
Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.
Recently, in response to the global challenge of COVID-19, Kinarus has initiated clinical evaluation of its combination therapy to treat patients suffering from SARS-CoV-2 infection. Kinarus has discovered that KIN001 has anti-viral activity against SARS-CoV-2, including against its variants of concern. KIN001 also possesses anti-inflammatory and anti-fibrotic activity.
2017
Served areaWorldwide
HeadquartersHochbergerstrasse 60C, 4057 Basel – Switzerland
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | ENG | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | ||||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
1,069,533,039
IPOJune 3, 2022
Stock exchange(s)SIX Swiss Exchange